CMN Weekly (21 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 21, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Hunterian Medicine
Main focus: Gene editing for the treatment of genetic diseases
Company stage: Pre-clinical
Diseases (gene editing): Undisclosed
Genome editing tool: CRISPR-MAD7, other undisclosed
Funding stage: Private
Location: Cambridge, MA, USA
Website: https://www.hunterian.com/
Partners: Inscripta
Hunterian Medicine aims to enable CRISPR delivery within the limited AAV packaging capacity that currently represents one of the major challenges within therapeutic genome editing. The company is exploring a range of diseases and orphan indications for licensing and/or development, although it has yet to disclose targets and indications for its lead therapeutic programme.
